Promoted Content
Promoted Content

Find Clinical Drug Pipelines for Nutrition and Weight Loss

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ASC41

            Therapeutic Area: Nutrition and Weight Loss Product Name: ASC41

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 22, 2021

            Details:

            The randomised, double-blind, placebo-controlled clinical study enrolled 20 overweight and obese participants with LDL-C greater than 110mg/dL. They were given ASC41 10mg oral tablets or a placebo once daily.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Semaglutide

            Therapeutic Area: Nutrition and Weight Loss Product Name: Ozempic

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 10, 2021

            Details:

            Northwestern University Feinberg School of Medicine in the US has reported that results from STEP 1 clinical trial of type-2 diabetes drug semaglutide (Ozempic) once weekly was linked to a sustained, clinically relevant reduction in body weight in obese adult participants.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nutritional therapies

            Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Nestle Health Sciences SA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 26, 2021

            Details:

            Senda Biosciences has entered into a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for a wide range of metabolic conditions, including obesity and glycemia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anamorelin HCl

            Therapeutic Area: Nutrition and Weight Loss Product Name: Adlumiz

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 22, 2021

            Details:

            Marketing approval of Adlumiz® (generic name: anamorelin hydrochloride) Tablet 50mg (“Adlumiz”) is mainly based on the results from the ONO-7643-04 and ONO-7643-05 studies conducted in Japan in patients with cancer cachexia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ART27.13

            Therapeutic Area: Nutrition and Weight Loss Product Name: ART27.13

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 09, 2020

            Details:

            Artelo’s ART27.13 is a G-Protein Coupled Receptor (GPCR) agonist and is being developed as a supportive care therapy for cancer patients suffering from anorexia and weight loss.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Semaglutide

            Therapeutic Area: Nutrition and Weight Loss Product Name: Ozempic

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 04, 2020

            Details:

            The submission is based on the results from the STEP phase 3a clinical trial programme. Across the STEP programme, people with obesity treated with once-weekly semaglutide 2.4 mg achieved a statistically significant and superior reduction in body weight compared to placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Oxprenolol

            Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-002

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 01, 2020

            Details:

            ACM-002 (S-oxprenolol) is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed. The new patent contains claims which cover the treatment of the symptoms of cachexia in patients having a late stage cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ART27.13

            Therapeutic Area: Nutrition and Weight Loss Product Name: ART27.13

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 29, 2020

            Details:

            ART27.13 is a highly potent, peripherally restricted synthetic, dual cannabinoid agonist believed to target peripheral CB1/CB2 receptors, and has the potential to increase appetite and food intake.